$GPCR News

Structure Therapeutics Announces Multiple Upcoming Presentations at ObesityWeek® 2026

Structure Therapeutics (GPCR) Stock May Be A Bargain Given Its Asset Base

Structure Therapeutics (GPCR) Gains Fresh Obesity Trial Backing Following Data That Keeps Valuation In Focus

Structure Therapeutics Inc. (GPCR) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Structure Therapeutics (GPCR): Will Repeat Dosing Confirm Its 3.3% Weight-Loss Signal?

Structure Therapeutics Inc. (GPCR) Discusses Positive Clinical Data Updates for Oral Small Molecule Amylin and GLP-1 Programs in Chronic Weight Management - Slideshow

Structure Therapeutics: The Amylin Data Changes The Math

Citizens Reiterates Market Outperform on Structure Therapeutics, Maintains $110 Price Target

Structure Therapeutics Inc. (GPCR) Discusses Positive Clinical Data Updates for Oral Small Molecule Amylin and GLP-1 Programs in Chronic Weight Management Transcript

Structure Therapeutics Reports Up to 16.2% Weight Loss in Aleniglipron Trial

Structure Therapeutics Advances Weight-Loss Pills With New Clinical Data

Structure Therapeutics Reports Positive Clinical Data Across Oral Small Molecule Amylin and GLP-1 Programs for Chronic Weight Management

Structure Therapeutics to Participate in Upcoming Healthcare Investor Conferences

NVO vs. GPCR: Which Obesity Stock Is the Better Buy Right Now?

Structure Therapeutics: A Strong Bet For An Oral GLP-1 Approval Before 2030

Citigroup Maintains Buy on Structure Therapeutics, Lowers Price Target to $97

Citizens Maintains Market Outperform on Structure Therapeutics, Lowers Price Target to $110

Structure Therapeutics Reports Second Quarter 2026 Financial Results and Recent Highlights

Structure Therapeutics (GPCR) Is A Hidden Biotech Multibagger Stock To Buy Now

Structure Therapeutics: My Top Small-Cap Pick For The Obesity Market (Upgrade)